artesunate-lapdap — Competitive Intelligence Brief

artesunate-lapdap (artesunate-lapdap) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Plasmodium falciparum dihydrofolate reductase (lapdap component); artemisinin mechanism not fully elucidated but involves heme interaction Infectious Disease Small molecule

Target snapshot

artesunate-lapdap (artesunate-lapdap) — London School of Hygiene and Tropical Medicine. Artesunate-lapdap is a fixed-dose combination that combines an artemisinin derivative with a diaminopyrimidine antifolate to kill malaria parasites through complementary mechanisms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
artesunate-lapdap TARGET	artesunate-lapdap	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination	Plasmodium falciparum dihydrofolate reductase (lapdap component); artemisinin mechanism not fully elucidated but involves heme interaction
Mefloquine- Artesunate	Mefloquine- Artesunate	Centers for Disease Control and Prevention	marketed	Antimalarial combination	Parasite heme detoxification pathway; artemisinin-iron adducts generating reactive oxygen species
chlorproguanil-dapsone plus artesunate	chlorproguanil-dapsone plus artesunate	Centers for Disease Control and Prevention	marketed	Antimalarial combination	Dihydrofolate reductase (chlorproguanil/dapsone); mitochondrial function (artesunate)
artemisinin/naphthoquine	artemisinin/naphthoquine	Ifakara Health Institute	marketed	Antimalarial combination	Plasmodium falciparum heme metabolism and mitochondrial electron transport
artemether-lumefantrine (ALN)	artemether-lumefantrine (ALN)	Jhpiego	marketed	Antimalarial combination	Plasmodium falciparum heme metabolism and parasite membranes
Chloroquine + Primaquine	Chloroquine + Primaquine	U.S. Army Medical Research and Development Command	marketed	Antimalarial combination	Plasmodium parasite heme metabolism and mitochondrial function
IPTp-DP	IPTp-DP	Kenya Medical Research Institute	marketed	Antimalarial combination therapy	Plasmodium falciparum (malaria parasite)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class